Note: DMA-25, DMA-50, and DMA-100 represent DMAMCL at doses of 25, 50, and 100 mg/kg, respectively. Inhibition represents the percent decrease in tumor weight compared to the vehicle group. *p < 0.05,

NIAID Data Ecosystem50

Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)

转移性结直肠癌维持与支持治疗

抗肿瘤药物疗效评估

PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work compared to main

NIAID Data Ecosystem40

An observational study of apatinib combined with XELOX regimen in postoperative adjuvant therapy of colorectal cancer

结直肠癌辅助化疗

抗肿瘤药物疗效评估

Interventions: experimental group:Apatinib combined with oxaliplatin and capecitabine (XELOX) g Primary outcome(s): Disease free survival Study Design: Single arm

NIAID Data Ecosystem80

热化疗吡柔比星和卡介盖林高危非肌层浸润性膀胱癌患者的 a retrospective study

膀胱癌治疗

抗肿瘤药物疗效评估

T t疗效和安全性胱热内化疗（HIVEC）吡柔比星（THP）卡介盖林（BCG 治疗高危非肌层浸润性膀胱癌（NMIBC）患者的膀

Figshare2023-12-10 更新40